术后护理干预对胃肠手术病人早期胃肠功能恢复的影响

目的:探究术后护理干预对胃肠手术病人早期胃肠功能恢复的影响。方法:选取本院2019年5月至2020年5月收治的胃肠手术病人共36例,按照随机数字表法分为观察组和对照组,每组各18例。比较两组胃肠手术病人肛门排气时间、肠鸣音恢复时间、首次排便时间以及不良反应率。结果:观察组胃肠手术病人肛门排气时间、肠鸣音恢复时间、首次排便时间均显著低于对照组(P<0.05)。观察组胃肠手术病人不良反应率显著低于对照组,差异有统计学意义(P<0.05)。结论:术后护理干预对胃肠手术病人早期胃肠功能恢复具有十分积极的影响,可以显著增强患者肠胃功能恢复水平,促使患者早日进食,增强身体免疫率。

术后护理对胃肠手术病人早期胃肠功能恢复的影响

探析胃肠手术病人早期胃肠功能恢复中术后护理的影响。方法:研究对象由2020年3月至8月于我院接受胃肠手术病人组成(78例),以随机数字表法分组,对照组行使常规护理(39例),实验组以术后护理干预(39例),将两组间临床相关指标、不良情绪进行对比。结果:不良情绪与临床相关指标恢复情况中两组均得到有效缓解,但实验组相对优于对照组,差异显赫,P<0.05。结论:胃肠手术患者经过术后护理干预,缩短了患者住院时间,且为其肠道功能恢复带来一定影响,值得临床广泛应用。

术后护理干预对胃肠手术病人早期胃肠功能恢复的影响评价研究

观察胃肠手术病人应用术后护理干预对早期胃肠功能恢复的影响。方法:数表法分组,对照组行常规护理,观察组行术后护理干预。结果:观察组肠鸣音恢复时间、肛门排气时间、排便时间、进食时间、住院时间等胃肠道恢复指标以及恶心呕吐、腹胀、肠梗阻、肠粘连、尿潴留等情况低于对照组,差异有统计学意义(P<0.05)。结论:对于胃肠手术病人而言,通过应用术后护理干预,可有效促进患者胃肠功能恢复,降低患者并发症情况,具有推广价值。

Postoperative sequential chemotherapy and radiotherapy for locally advanced gastric cancer

Objective The aim of the study was to evaluate the role of postoperative sequential chemotherapy and radiotherapy in patients with locally advanced gastric cancer.Methods From January 2003 to December 2010, 146 gastric cancer patients at our institution(Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) received postoperative sequential chemotherapy and radiotherapy after radical surgery. Radiotherapy was administered as a dose of 4500 cGy in 25 fractions. For patients with positive margins, the dose was raised to 5040 cGy in 28 fractions. Three cycles of m FOLFOX or PF(cisplatin, 5-fluorouracil) chemotherapy regimen were applied before and after radiotherapy. Three-and 5-year survival rates were analyzed; any adverse effects with respect to hematology, hepatic and renal function, or the gastrointestinal tract that occurred during the treatment were evaluated.Results This cohort consisted of non-metastatic patients: 104 men and 42 women with a median age of 51.0 years. The full course of sequential chemotherapy and radiotherapy(4500–5040 cGy) was completed by 129 patients(88.4%). Seventeen regional relapses(9.8%) and 46 distant relapses(23.8%) were recorded. Fifty patients(34.2%) died during follow-up. The 3-and 5-year overall survival rates(OS) were 60% and 54%, and disease-free survival rates(DFS) were 53% and 47%, respectively. There were no significant differences in survival rate with respect to age, sex, histopathology, N stage, site of the tumor, or margin status. Multivariate analysis showed that only the depth of tumor invasion(T stage) was an independent prognostic factor for OS(P = 0.009) and DFS(P = 0.006). The rates of grades 3 and 4 neutropenia and vomiting were 9.6% and 3.4%, respectively, during the treatment.Conclusion Postoperative sequential chemotherapy with an m FOLFOX or PF regimen and radiotherapy were found to be an effective means of treating advanced gastric cancer patients with T3–T4 disease. The adverse effects of this treatment were tolerable.